Cholesterol metabolism: physiological regulation and diseases

Abstract

Cholesterol homeostasis is crucial for cellular and systemic function. The disorder of cholesterol metabolism not only accelerates the onset of cardiovascular disease (CVD) but is also the fundamental cause of other ailments. The regulation of cholesterol metabolism in the human is an extremely complex process. Due to the dynamic balance between cholesterol synthesis, intake, efflux and storage, cholesterol metabolism generally remains secure. Disruption of any of these links is likely to have adverse effects on the body. At present, increasing evidence suggests that abnormal cholesterol metabolism is closely related to various systemic diseases. However, the exact mechanism by which cholesterol metabolism contributes to disease pathogenesis remains unclear, and there are still unknown factors. In this review, we outline the metabolic process of cholesterol in the human body, especially reverse cholesterol transport (RCT). Then, we discuss separately the impact of abnormal cholesterol metabolism on common diseases and potential therapeutic targets for each disease, including CVD, tumors, neurological diseases, and immune system diseases. At the end of this review, we focus on the effect of cholesterol metabolism on eye diseases. In short, we hope to provide more new ideas for the pathogenesis and treatment of diseases from the perspective of cholesterol.

Keywords

cholesterol / cholesterol metabolism / diseases / efflux / reverse cholesterol transport / regulation

References

[1] Luu W, Sharpe LJ, Capell-Hattam I, Gelissen IC, Brown AJ. Oxysterols: old tale, new twists. Annu Rev Pharmacol Toxicol. 2016;56:447-467.

[2] Okuhira K. [Challenges in drug development targeting anti-atherosclerotic proteins]. Yakugaku Zasshi. 2020;140(2):153-157.

[3] Pikuleva IA, Curcio CA. Cholesterol in the retina: the best is yet to come. Prog Retin Eye Res. 2014;41:64-89.

[4] Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell. 2015;6(4):254-264.

[5] Meng Y, Wang Q, Lyu Z. Cholesterol metabolism and tumor. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021;50(1):23-31.

[6] Courtney R, Landreth GE. LXR regulation of brain cholesterol: from development to disease. Trends Endocrinol Metab. 2016;27(6):404-414.

[7] Conley YP, Thalamuthu A, Jakobsdottir J, et al. Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy. Hum Mol Genet. 2005;14(14):1991-2002.

[8] Neale BM, Fagerness J, Reynolds R, et al. Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). Proc Natl Acad Sci USA. 2010;107(16):7395-7400.

[9] Chen W, Stambolian D, Edwards AO, et al. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci USA. 2010;107(16):7401-7406.

[10] Zhang X, Wang K, Zhu L, Wang Q. Reverse cholesterol transport pathway and cholesterol efflux in diabetic retinopathy. J Diabetes Res. 2021;2021:8746114.

[11] Cardoso D, Perucha E. Cholesterol metabolism: a new molecular switch to control inflammation. Clin Sci (Lond). 2021;135(11):1389-1408.

[12] Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res. 1983;22(2):79-131.

[13] Mitsche MA, McDonald JG, Hobbs HH, Cohen JC. Flux analysis of cholesterol biosynthesis in vivo reveals multiple tissue and cell-type specific pathways. Elife. 2015;4:e07999.

[14] Hubler Z, Friedrich RM, Sax JL, et al. Modulation of lanosterol synthase drives 24,25-epoxysterol synthesis and oligodendrocyte formation. Cell Chem Biol. 2021;28(6):866-875. e5.

[15] Horton JD, Shah NA, Warrington JA, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA. 2003;100(21):12027-12032.

[16] Li Y, Song Y, Zhao M, et al. A novel role for CRTC2 in hepatic cholesterol synthesis through SREBP-2. Hepatology. 2017;66(2):481-497.

[17] Tao R, Xiong X, DePinho RA, Deng CX, Dong XC. Hepatic SREBP-2 and cholesterol biosynthesis are regulated by FoxO3 and Sirt6. J Lipid Res. 2013;54(10):2745-2753.

[18] Yang T, Espenshade PJ, Wright ME, et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell. 2002;110(4):489-500.

[19] Yabe D, Brown MS, Goldstein JL. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci USA. 2002;99(20):12753-12758.

[20] Vergnes L, Chin RG, de Aguiar Vallim T, et al. SREBP-2-deficient and hypomorphic mice reveal roles for SREBP-2 in embryonic development and SREBP-1c expression. J Lipid Res. 2016;57(3):410-421.

[21] Giandomenico V, Simonsson M, Grönroos E, Ericsson J. Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol Cell Biol. 2003;23(7):2587-2599.

[22] Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA. 2007;104(31):12861-12866.

[23] Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 2011;13(4):376-388.

[24] Eid W, Dauner K, Courtney KC, et al. mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells. Proc Natl Acad Sci USA. 2017;114(30):7999-8004.

[25] Peterson TR, Sengupta SS, Harris TE, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell. 2011;146(3):408-420.

[26] Altmann SW, Davis HR,, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201-1204.

[27] Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. Jama. 2009;302(18):1993-2000.

[28] Saito H, Dhanasekaran P, Nguyen D, et al. Alpha-helix formation is required for high affinity binding of human apolipoprotein A-I to lipids. J Biol Chem. 2004;279(20):20974-20981.

[29] Hong YF, Kim H, Kim HS, Park WJ, Kim JY, Chung DK. Lactobacillus acidophilus K301 inhibits atherogenesis via induction of 24 (S), 25-epoxycholesterol-mediated ABCA1 and ABCG1 production and cholesterol efflux in macrophages. PLoS One. 2016;11(4):e0154302.

[30] Choudhary M, Tayyari F, Handa JT, Malek G. Characterization and identification of measurable endpoints in a mouse model featuring age-related retinal pathologies: a platform to test therapies. Lab Invest. 2022;102(10):1132-1142.

[31] Saadane A, Petrov A, Mast N, et al. Mechanisms that minimize retinal impact of apolipoprotein E absence. J Lipid Res. 2018;59(12):2368-2382.

[32] Laffitte BA, Repa JJ, Joseph SB, et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A. 2001;98(2):507-512.

[33] La Cunza N, Tan LX, Thamban T, et al. Mitochondria-dependent phase separation of disease-relevant proteins drives pathological features of age-related macular degeneration. JCI Insight. 2021;6(9):e142254.

[34] Malek G, Li CM, Guidry C, Medeiros NE, Curcio CA. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol. 2003;162(2):413-425.

[35] Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann Neurol. 1993;34(5):752-754.

[36] Klaver CC, Kliffen M, van Duijn CM, et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet. 1998;63(1):200-206.

[37] Fan D, Qiu S, Overton CD, et al. Impaired secretion of apolipoprotein E2 from macrophages. J Biol Chem. 2007;282(18):13746-13753.

[38] Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol. 1994;14(10):7025-7035.

[39] Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 1997;46(8):1319-1327.

[40] Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 1995;9(9):1033-1045.

[41] Edwards PA, Kennedy MA, Mak PA. LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vascul Pharmacol. 2002;38(4):249-256.

[42] Laffitte BA, Chao LC, Li J, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A. 2003;100(9):5419-5424.

[43] Hazra S, Rasheed A, Bhatwadekar A, et al. Liver X receptor modulates diabetic retinopathy outcome in a mouse model of streptozotocin-induced diabetes. Diabetes. 2012;61(12):3270-3279.

[44] El-Darzi N, Mast N, Buchner DA, et al. Low-dose anti-HIV drug efavirenz mitigates retinal vascular lesions in a mouse model of Alzheimer's disease. Front Pharmacol. 2022;13:902254.

[45] Oram JF, Vaughan AM. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res. 2006;99(10):1031-1043.

[46] Orsó E, Broccardo C, Kaminski WE, et al. Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. Nat Genet. 2000;24(2):192-196.

[47] Kennedy MA, Barrera GC, Nakamura K, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005;1(2):121-131.

[48] Vaughan AM, Oram JF. ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. J Biol Chem. 2005;280(34):30150-30157.

[49] Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-e596.

[50] Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque. Trends Cardiovasc Med. 2019;29(8):451-455.

[51] Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001;104(4):503-516.

[52] Varghese JF, Patel R, Yadav UCS. Sterol regulatory element binding protein (SREBP)-1 mediates oxidized low-density lipoprotein (oxLDL) induced macrophage foam cell formation through NLRP3 inflammasome activation. Cell Signal. 2019;53:316-326.

[53] He XW, Yu D, Li WL, et al. Anti-atherosclerotic potential of baicalin mediated by promoting cholesterol efflux from macrophages via the PPARgamma-LXRalpha-ABCA1/ABCG1 pathway. Biomed Pharmacother. 2016;83:257-264.

[54] Gui YZ, Yan H, Gao F, Xi C, Li HH, Wang YP. Betulin attenuates atherosclerosis in apoE(-/-) mice by up-regulating ABCA1 and ABCG1. Acta Pharmacol Sin. 2016;37(10):1337-1348.

[55] Brümmer A, Hausser J. MicroRNA binding sites in the coding region of mRNAs: extending the repertoire of post-transcriptional gene regulation. Bioessays. 2014;36(6):617-626.

[56] Baldan A, de Aguiar Vallim TQ. miRNAs and high-density lipoprotein metabolism. Biochim Biophys Acta. 2016;1861(12 Pt B):2053-2061.

[57] Liang B, Wang X, Song X, et al. MicroRNA-20a/b regulates cholesterol efflux through post-transcriptional repression of ATP-binding cassette transporter A1. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862(9):929-938.

[58] Meiler S, Baumer Y, Toulmin E, Seng K, Boisvert WA. MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35(2):323-331.

[59] Lu X, Yang B, Yang H, et al. MicroRNA-320b modulates cholesterol efflux and atherosclerosis. J Atheroscler Thromb. 2022;29(2):200-220.

[60] Zhao R, Feng J, He G. miR-613 regulates cholesterol efflux by targeting LXRalpha and ABCA1 in PPARgamma activated THP-1 macrophages. Biochem Biophys Res Commun. 2014;448(3):329-334.

[61] Liu H, Zuo C, Cao L, Yang N, Jiang T. Inhibition of miR-652-3p regulates lipid metabolism and inflammatory cytokine secretion of macrophages to alleviate atherosclerosis by improving TP53 expression. Mediators Inflamm. 2022;2022:9655097.

[62] Kong J, Liu L, Song L, Zhao R, Feng Y. MicroRNA miR-34a-5p inhibition restrains oxidative stress injury of macrophages by targeting MDM4. Vascular. 2023;31(3):608-618.

[63] Sui Z, Zhou J, Cheng Z, Lu P. Squalene epoxidase (SQLE) promotes the growth and migration of the hepatocellular carcinoma cells. Tumour Biol. 2015;36(8):6173-6179.

[64] Zhang Z, Wu W, Jiao H, et al. Squalene epoxidase promotes hepatocellular carcinoma development by activating STRAP transcription and TGF-beta/SMAD signalling. Br J Pharmacol. 2023;180(12):1562-1581.

[65] Ashida S, Kawada C, Inoue K. Stromal regulation of prostate cancer cell growth by mevalonate pathway enzymes HMGCS1 and HMGCR. Oncol Lett. 2017;14(6):6533-6542.

[66] Kalogirou C, Linxweiler J, Schmucker P, et al. MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. Nat Commun. 2021;12(1):5066.

[67] Chushi L, Wei W, Kangkang X, Yongzeng F, Ning X, Xiaolei C. HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells. Gene. 2016;587(1):42-47.

[68] Qiu Z, Yuan W, Chen T, et al. HMGCR positively regulated the growth and migration of glioblastoma cells. Gene. 2016;576(1 Pt 1):22-27.

[69] Singh R, Yadav V, Kumar S, Saini N. MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci Rep. 2015;5:17454.

[70] Zhong C, Fan L, Yao F, Shi J, Fang W, Zhao H. HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc. Tumour Biol. 2014;35(5):4123-4129.

[71] Ge H, Zhao Y, Shi X, et al. Squalene epoxidase promotes the proliferation and metastasis of lung squamous cell carcinoma cells though extracellular signal-regulated kinase signaling. Thorac Cancer. 2019;10(3):428-436.

[72] Zou F, Chen W, Song T, et al. SQLE Knockdown inhibits bladder cancer progression by regulating the PTEN/AKT/GSK3β signaling pathway through P53. Cancer Cell Int. 2023;23(1):221.

[73] He L, Li H, Pan C, et al. Squalene epoxidase promotes colorectal cancer cell proliferation through accumulating calcitriol and activating CYP24A1-mediated MAPK signaling. Cancer Commun (Lond). 2021;41(8):726-746.

[74] Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044.

[75] Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst. 2011;103(11):885-892.

[76] Kitahara CM, Berrington de González A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29(12):1592-1598.

[77] Tulloch-Reid MK, McFarlane-Anderson N, Bennett FI, Aiken WD, Jackson MD. Effects of cholesterol, C-reactive protein, and interleukin-6 on prostate cancer risk in a population of African ancestry. Cancer Causes Control. 2017;28(11):1313-1321.

[78] Masko EM, Allott EH, Freedland SJ. The relationship between nutrition and prostate cancer: is more always better? Eur Urol. 2013;63(5):810-820.

[79] Schaffner CP. Prostatic cholesterol metabolism: regulation and alteration. Prog Clin Biol Res. 1981;75a:279-324.

[80] El-Kenawi A, Dominguez-Viqueira W, Liu M, et al. Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer. Cancer Res. 2021;81(21):5477-5490.

[81] Pan T, Lin SC, Lee YC, et al. Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. Oncogene. 2021;40(27):4592-4603.

[82] Ossoli A, Giorgio E, Cetti F, et al. HDL-mediated reduction of cholesterol content inhibits the proliferation of prostate cancer cells induced by LDL: Role of ABCA1 and proteasome inhibition. Biofactors. 2022;48(3):707-717.

[83] Raza S, Meyer M, Goodyear C, Hammer KDP, Guo B, Ghribi O. The cholesterol metabolite 27-hydroxycholesterol stimulates cell proliferation via ERbeta in prostate cancer cells. Cancer Cell Int. 2017;17:52.

[84] Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115(4):959-968.

[85] Freeman MR, Cinar B, Kim J, et al. Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes. Steroids. 2007;72(2):210-217.

[86] Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res. 2002;62(8):2227-2231.

[87] Toren P, Zoubeidi A. Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review). Int J Oncol. 2014;45(5):1793-1801.

[88] Pommier AJ, Alves G, Viennois E, et al. Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene. 2010;29(18):2712-2723.

[89] Mak B, Lin HM, Duong T, et al. Modulation of plasma lipidomic profiles in metastatic castration-resistant prostate cancer by simvastatin. Cancers (Basel). 2022;14(19):4792.

[90] Liang Y, Mafuvadze B, Aebi JD, Hyder SM. Cholesterol biosynthesis inhibitor RO 48–8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells. Onco Targets Ther. 2016;9:3223-3232.

[91] Stopsack KH, Gerke TA, Sinnott JA, et al. Cholesterol metabolism and prostate cancer lethality. Cancer Res. 2016;76(16):4785-4790.

[92] Stopsack KH, Gerke TA, Andrén O, et al. Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis. 2017;38(8):806-811.

[93] Xu Z, Huang L, Dai T, et al. SQLE mediates metabolic reprogramming to promote LN metastasis in castration-resistant prostate cancer. Onco Targets Ther. 2021;14:4285-4295.

[94] Lee SS, Li J, Tai JN, Ratliff TL, Park K, Cheng JX. Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment. ACS Nano. 2015;9(3):2420-2432.

[95] Lee HJ, Li J, Vickman RE, et al. Cholesterol esterification inhibition suppresses prostate cancer metastasis by impairing the Wnt/beta-catenin pathway. Mol Cancer Res. 2018;16(6):974-985.

[96] Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.

[97] McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4-13.

[98] El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118-1127.

[99] Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology. 2007;72(Suppl 1):30-44.

[100] Ioannou GN, Morrow OB, Connole ML, Lee SP. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology. 2009;50(1):175-184.

[101] Peng L, Yan Q, Chen Z, et al. Research progress on the role of cholesterol in hepatocellular carcinoma. Eur J Pharmacol. 2023;938:175410.

[102] Wang Y, Wang J, Li X, et al. N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism. Nat Commun. 2021;12(1):6314.

[103] Nuño-Lámbarri N, Domínguez-Pérez M, Baulies-Domenech A, et al. Liver cholesterol overload aggravates obstructive cholestasis by inducing oxidative stress and premature death in mice. Oxid Med Cell Longev. 2016;2016:9895176.

[104] Domínguez-Pérez M, Nuño-Lámbarri N, Clavijo-Cornejo D, et al. Hepatocyte growth factor reduces free cholesterol-mediated lipotoxicity in primary hepatocytes by countering oxidative stress. Oxid Med Cell Longev. 2016;2016:7960386.

[105] Gomez-Quiroz LE, Seo D, Lee YH, et al. Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress. Toxicology. 2016;361-362:39-48.

[106] Enríquez-Cortina C, Bello-Monroy O, Rosales-Cruz P, et al. Cholesterol overload in the liver aggravates oxidative stress-mediated DNA damage and accelerates hepatocarcinogenesis. Oncotarget. 2017;8(61):104136-104148.

[107] Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21(4):504-516.

[108] He M, Zhang W, Dong Y, et al. Pro-inflammation NF-κB signaling triggers a positive feedback via enhancing cholesterol accumulation in liver cancer cells. J Exp Clin Cancer Res. 2017;36(1):15.

[109] Shao WQ, Zhu WW, Luo MJ, et al. Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma. Cell Rep. 2022;39(3):110712.

[110] Hu HH, Chen DQ, Wang YN, et al. New insights into TGF-β/Smad signaling in tissue fibrosis. Chem Biol Interact. 2018;292:76-83.

[111] Chen L, Yang T, Lu DW, et al. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment. Biomed Pharmacother. 2018;101:670-681.

[112] Hu C, Liu D, Zhang Y, et al. LXRalpha-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells. Oncogene. 2014;33(22):2888-2897.

[113] Xiong H, Zhang Y, Chen S, et al. Induction of SOCS3 by liver X receptor suppresses the proliferation of hepatocellular carcinoma cells. Oncotarget. 2017;8(38):64083-64094.

[114] Xie Y, Sun R, Gao L, et al. Chronic activation of LXRalpha sensitizes mice to hepatocellular carcinoma. Hepatol Commun. 2022;6(5):1123-1139.

[115] Fan M, Chen Z, Shao W, et al. SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway. Acta Biochim Biophys Sin (Shanghai). 2023;55(9):1479-1486.

[116] Yue X, Kong Y, Zhang Y, et al. SREBF2-STARD4 axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis. Cancer Sci. 2023;114(2):477-489.

[117] Dietschy JM, Turley SD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res. 2004;45(8):1375-1397.

[118] Goritz C, Mauch DH, Pfrieger FW. Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. Mol Cell Neurosci. 2005;29(2):190-201.

[119] Fester L, Zhou L, Bütow A, et al. Cholesterol-promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus. Hippocampus. 2009;19(8):692-705.

[120] Linetti A, Fratangeli A, Taverna E, et al. Cholesterol reduction impairs exocytosis of synaptic vesicles. J Cell Sci. 2010;123(Pt 4):595-605.

[121] Liu Q, Trotter J, Zhang J, et al. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J Neurosci. 2010;30(50):17068-17078.

[122] Liu Q, Zerbinatti CV, Zhang J, et al. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron. 2007;56(1):66-78.

[123] Luo Y, Tan X, Zhang X, Li Y, Huang J, Deng Y. Effect of liver X receptor agonist TO901317 on cognitive function in APP/PS1 double transgenic mice with Alzheimer's disease and the underlying mechanism. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022;47(10):1324-1331.

[124] Djelti F, Braudeau J, Hudry E, et al. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. Brain. 2015;138(Pt 8):2383-2398.

[125] Yassine HN, Feng Q, Chiang J, et al. ABCA1-mediated cholesterol efflux capacity to cerebrospinal fluid is reduced in patients with mild cognitive impairment and Alzheimer's disease. J Am Heart Assoc. 2016;5(2):e002886.

[126] Lee SI, Jeong W, Lim H, et al. APOE4-carrying human astrocytes oversupply cholesterol to promote neuronal lipid raft expansion and Abeta generation. Stem Cell Reports. 2021;16(9):2128-2137.

[127] Paul R, Choudhury A, Kumar S, Giri A, Sandhir R, Borah A. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress. PLoS One. 2017;12(2):e0171285.

[128] Griffiths WJ, Abdel-Khalik J, Moore SF, et al. The cerebrospinal fluid profile of cholesterol metabolites in Parkinson's Disease and their association with disease state and clinical features. Front Aging Neurosci. 2021;13:685594.

[129] Rayaprolu S, Higginbotham L, Bagchi P, et al. Systems-based proteomics to resolve the biology of Alzheimer's disease beyond amyloid and tau. Neuropsychopharmacology. 2021;46(1):98-115.

[130] Sun BL, Chen Y, Fan DY, Zhu C, Zeng F, Wang YJ. Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives. Sci China Life Sci. 2021;64(6):926-937.

[131] Bai X, Mai M, Yao K, et al. The role of DHCR24 in the pathogenesis of AD: re-cognition of the relationship between cholesterol and AD pathogenesis. Acta Neuropathol Commun. 2022;10(1):35.

[132] Borràs C, Mercer A, Sirisi S, et al. HDL-like-Mediated Cell Cholesterol Trafficking in the Central Nervous System and Alzheimer's Disease Pathogenesis. Int J Mol Sci. 2022;23(16):9356.

[133] Mai M, Guo X, Huang Y, et al. DHCR24 knockdown induces tau hyperphosphorylation at Thr181, Ser199, Ser262, and Ser396 sites via activation of the lipid raft-dependent Ras/MEK/ERK signaling pathway in C8D1A astrocytes. Mol Neurobiol. 2022;59(9):5856-5873.

[134] Zhang WB, Huang Y, Guo XR, Zhang MQ, Yuan XS, Zu HB. DHCR24 reverses Alzheimer's disease-related pathology and cognitive impairment via increasing hippocampal cholesterol levels in 5xFAD mice. Acta Neuropathol Commun. 2023;11(1):102.

[135] Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence. Acta Neurol Scand Suppl. 2006;185:50-57.

[136] Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014;71(2):195-200.

[137] Loera-Valencia R, Vazquez-Juarez E, Muñoz A, et al. High levels of 27-hydroxycholesterol results in synaptic plasticity alterations in the hippocampus. Sci Rep. 2021;11(1):3736.

[138] Wang T, Cui S, Hao L, et al. Regulation of Th17/Treg balance by 27-hydroxycholesterol and 24S-hydroxycholesterol correlates with learning and memory ability in mice. Int J Mol Sci. 2022;23(8):4370.

[139] Ramirez DM, Andersson S, Russell DW. Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J Comp Neurol. 2008;507(5):1676-1693.

[140] Maioli S, Båvner A, Ali Z, et al. Is it possible to improve memory function by upregulation of the cholesterol 24S-hydroxylase (CYP46A1) in the brain? PLoS One. 2013;8(7):e68534.

[141] Petrov AM, Lam M, Mast N, et al. CYP46A1 activation by efavirenz leads to behavioral improvement without significant changes in amyloid plaque load in the brain of 5XFAD mice. Neurotherapeutics. 2019;16(3):710-724.

[142] Szwast SJ, Hendrie HC, Lane KA, et al. Association of statin use with cognitive decline in elderly African Americans. Neurology. 2007;69(19):1873-1880.

[143] Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol. 2005;62(7):1047-1051.

[144] Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021;20(5):385-397.

[145] Dirkx MF, Zach H, Bloem BR, Hallett M, Helmich RC. The nature of postural tremor in Parkinson disease. Neurology. 2018;90(13):e1095-e1103.

[146] Rana AQ, Siddiqui I, Mosabbir AA, Qureshi AR, Fattah A, Awan N. Is action tremor in Parkinson's disease related to resting tremor? Neurol Res. 2014;36(2):107-111.

[147] Yan J, Qiao L, Tian J, et al. Effect of statins on Parkinson's disease: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(12):e14852.

[148] Carroll CB, Wyse RKH. Simvastatin as a potential disease-modifying therapy for patients with Parkinson's disease: rationale for clinical trial, and current progress. J Parkinsons Dis. 2017;7(4):545-568.

[149] Huang X, Alonso A, Guo X, et al. Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study. Mov Disord. 2015;30(4):552-559.

[150] Jeong SH, Lee HS, Chung SJ, et al. Effects of statins on dopamine loss and prognosis in Parkinson's disease. Brain. 2021;144(10):3191-3200.

[151] Mohamed A, Chen Y, Wu H, Liao J, Cheng B, Lu Q. Therapeutic advances in the treatment of SLE. Int Immunopharmacol. 2019;72:218-223.

[152] Lo MS, Tsokos GC. Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy. Curr Opin Rheumatol. 2018;30(2):222-228.

[153] López-Pedrera C, Aguirre M, Barbarroja N, Cuadrado MJ. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol. 2010;2010:607084.

[154] Quevedo-Abeledo JC, Sánchez-Pérez H, Tejera-Segura B, et al. Differences in capacity of high-density lipoprotein cholesterol efflux between patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(11):1590-1596.

[155] Ronda N, Favari E, Borghi MO, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2014;73(3):609-615.

[156] Voloshyna I, Teboul I, Littlefield MJ, et al. Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux. Exp Biol Med (Maywood). 2016;241(14):1611-1619.

[157] Ruiz-Limon P, Barbarroja N, Perez-Sanchez C, et al. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Ann Rheum Dis. 2015;74(7):1450-1458.

[158] Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15.

[159] Amezaga Urruela M, Suarez-Almazor ME. Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies. Curr Rheumatol Rep. 2012;14(5):428-437.

[160] Pérez-Baos S, Barrasa JI, Gratal P, et al. Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. Br J Pharmacol. 2017;174(18):3018-3031.

[161] Xie Y, Feng SL, Mai CT, et al. Suppression of up-regulated LXRα by silybin ameliorates experimental rheumatoid arthritis and abnormal lipid metabolism. Phytomedicine. 2021;80:153339.

[162] Dragoljevic D, Lee MKS, Pernes G, et al. Administration of an LXR agonist promotes atherosclerotic lesion remodelling in murine inflammatory arthritis. Clin Transl Immunol. 2023;12(4):e1446.

[163] Ban N, Lee TJ, Sene A, et al. Impaired monocyte cholesterol clearance initiates age-related retinal degeneration and vision loss. JCI Insight. 2018;3(17):e120824.

[164] Storti F, Raphael G, Griesser V, et al. Regulated efflux of photoreceptor outer segment-derived cholesterol by human RPE cells. Exp Eye Res. 2017;165:65-77.

[165] Peters F, Ebner LJA, Atac D, et al. Regulation of ABCA1 by AMD-associated genetic variants and hypoxia in iPSC-RPE. Int J Mol Sci. 2022;23(6):3194.

[166] Alamri A, Biswas L, Watson DG, Shu X. Deletion of TSPO resulted in change of metabolomic profile in retinal pigment epithelial cells. Int J Mol Sci. 2019;20(6):1387.

[167] Nakano-Ito K, Fujikawa Y, Hihara T, et al. E2012-induced cataract and its predictive biomarkers. Toxicol Sci. 2014;137(1):249-258.

[168] Miyashita T, Senshu M, Ibi K, et al. Evaluation of lens opacity due to inhibition of cholesterol biosynthesis using rat lens explant cultures. Toxicology. 2022;465:153064.

[169] Zhao M, Mei T, Shang B, et al. Defect of LSS disrupts lens development in cataractogenesis. Front Cell Dev Biol. 2021;9:788422.

[170] Ishida H, Shibata T, Nakamura Y, et al. Identification of Differential gene expression pattern in lens epithelial cells derived from cataractous and noncataractous lenses of Shumiya cataract rat. Biomed Res Int. 2020;2020:7319590.

[171] Flores R, Jin X, Chang J, et al. LCAT, ApoD, and ApoA1 expression and review of cholesterol deposition in the cornea. Biomolecules. 2019;9(12):785.

[172] Aldaas KM, Ismail OM, Hakim J, et al. Association of dry eye disease with dyslipidemia and statin use. Am J Ophthalmol. 2020;218:54-58.

[173] Jiang SY, Tang JJ, Xiao X, et al. Schnyder corneal dystrophy-associated UBIAD1 mutations cause corneal cholesterol accumulation by stabilizing HMG-CoA reductase. PLoS Genet. 2019;15(7):e1008289.

[174] Saadane A, Mast N, Trichonas G, et al. Retinal vascular abnormalities and microglia activation in mice with deficiency in cytochrome P450 46A1-mediated cholesterol removal. Am J Pathol. 2019;189(2):405-425.

[175] Vujosevic S, Alovisi C, Chakravarthy U. Epidemiology of geographic atrophy and its precursor features of intermediate age-related macular degeneration. Acta Ophthalmol. 2023;101(8):839-856.

[176] Liu K, Xie B. Today and future of age-related macular degeneration. ISRN Ophthalmol. 2012;2012:480212.

[177] Wang L, Clark ME, Crossman DK, et al. Abundant lipid and protein components of drusen. PLoS One. 2010;5(4):e10329.

[178] Rodriguez IR, Alam S, Lee JW. Cytotoxicity of oxidized low-density lipoprotein in cultured RPE cells is dependent on the formation of 7-ketocholesterol. Invest Ophthalmol Vis Sci. 2004;45(8):2830-2837.

[179] Rodriguez IR, Clark ME, Lee JW, Curcio CA. 7-ketocholesterol accumulates in ocular tissues as a consequence of aging and is present in high levels in drusen. Exp Eye Res. 2014;128:151-155.

[180] Yang C, Xie L, Gu Q, Qiu Q, Wu X, Yin L. 7-Ketocholesterol disturbs RPE cells phagocytosis of the outer segment of photoreceptor and induces inflammation through ERK signaling pathway. Exp Eye Res. 2019;189:107849.

[181] Bergmann M, Schütt F, Holz FG, Kopitz J. Inhibition of the ATP-driven proton pump in RPE lysosomes by the major lipofuscin fluorophore A2-E may contribute to the pathogenesis of age-related macular degeneration. Faseb j. 2004;18(3):562-564.

[182] Vives-Bauza C, Anand M, Shiraz AK, et al. The age lipid A2E and mitochondrial dysfunction synergistically impair phagocytosis by retinal pigment epithelial cells. J Biol Chem. 2008;283(36):24770-24780.

[183] Hammer M, Richter S, Guehrs KH, Schweitzer D. Retinal pigment epithelium cell damage by A2-E and its photo-derivatives. Mol Vis. 2006;12:1348-1354.

[184] Biswas L, Zeng Z, Graham A, Shu X. Gypenosides mediate cholesterol efflux and suppress oxidized LDL induced inflammation in retinal pigment epithelium cells. Exp Eye Res. 2020;191:107931.

[185] Huang JD, Amaral J, Lee JW, Rodriguez IR. 7-Ketocholesterol-induced inflammation signals mostly through the TLR4 receptor both in vitro and in vivo. PLoS One. 2014;9(7):e100985.

[186] Kauppinen A, Niskanen H, Suuronen T, Kinnunen K, Salminen A, Kaarniranta K. Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells–implications for age-related macular degeneration (AMD). Immunol Lett. 2012;147(1-2):29-33.

[187] Shimada K, Crother TR, Karlin J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36(3):401-414.

[188] Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12(3):222-230.

[189] Luthra S, Fardin B, Dong J, et al. Activation of caspase-8 and caspase-12 pathways by 7-ketocholesterol in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2006;47(12):5569-5575.

[190] Neekhra A, Luthra S, Chwa M, et al. Caspase-8, -12, and -3 activation by 7-ketocholesterol in retinal neurosensory cells. Invest Ophthalmol Vis Sci. 2007;48(3):1362-1367.

[191] Luthra S, Dong J, Gramajo AL, et al. 7-Ketocholesterol activates caspases-3/7, -8, and -12 in human microvascular endothelial cells in vitro. Microvasc Res. 2008;75(3):343-350.

[192] Wang H, Han X, Kunz E, Hartnett ME. Thy-1 regulates VEGF-mediated choroidal endothelial cell activation and migration: implications in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2016;57(13):5525-5534.

[193] Gehlbach P, Li T, Hatef E. Statins for age-related macular degeneration. Cochrane Database Syst Rev. 2016;2016(8):Cd006927.

[194] Memarzadeh E, Heidari-Soureshjani S. The relationship between statin and risk of age-related macular degeneration: a systematic review and meta-analysis. J Ophthalmol. 2022;2022:8564818.

[195] Mast N, Bederman IR, Pikuleva IA. Retinal cholesterol content is reduced in simvastatin-treated mice due to inhibited local biosynthesis albeit increased uptake of serum cholesterol. Drug Metab Dispos. 2018;46(11):1528-1537.

[196] Alpy F, Tomasetto C. Give lipids a START: the StAR-related lipid transfer (START) domain in mammals. J Cell Sci. 2005;118(Pt 13):2791-2801.

[197] Clark BJ, Soo SC, Caron KM, Ikeda Y, Parker KL, Stocco DM. Hormonal and developmental regulation of the steroidogenic acute regulatory protein. Mol Endocrinol. 1995;9(10):1346-1355.

[198] Taylor JM, Borthwick F, Bartholomew C, Graham A. Overexpression of steroidogenic acute regulatory protein increases macrophage cholesterol efflux to apolipoprotein AI. Cardiovasc Res. 2010;86(3):526-534.

[199] Wilhelm LP, Wendling C, Védie B, et al. STARD3 mediates endoplasmic reticulum-to-endosome cholesterol transport at membrane contact sites. Embo J. 2017;36(10):1412-1433.

[200] Almarhoun M, Biswas L, Alhasani RH, et al. Overexpression of STARD3 attenuates oxidized LDL-induced oxidative stress and inflammation in retinal pigment epithelial cells. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(7):158927.

[201] Liu J, Rone MB, Papadopoulos V. Protein-protein interactions mediate mitochondrial cholesterol transport and steroid biosynthesis. J Biol Chem. 2006;281(50):38879-38893.

[202] Biswas L, Farhan F, Reilly J, Bartholomew C, Shu X. TSPO ligands promote cholesterol efflux and suppress oxidative stress and inflammation in choroidal endothelial cells. Int J Mol Sci. 2018;19(12):3740.

[203] Biswas L, Ibrahim KS, Li X, et al. Effect of a TSPO ligand on retinal pigment epithelial cholesterol homeostasis in high-fat fed mice, implication for age-related macular degeneration. Exp Eye Res. 2021;208:108625.

[204] Farhan F, Almarhoun M, Wong A, et al. Deletion of TSPO causes dysregulation of cholesterol metabolism in mouse retina. Cells. 2021;10(11):3066.

[205] Rone MB, Fan J, Papadopoulos V. Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. Biochim Biophys Acta. 2009;1791(7):646-658.

[206] Xie L, Gu Q, Wu X, Yin L. Activation of LXRs reduces oxysterol lipotoxicity in RPE cells by promoting mitochondrial function. Nutrients. 2022;14(12):2473.

[207] Ashraf F, Cogan DG, Kruth HS. Apolipoprotein A-I and B distribution in the human cornea. Invest Ophthalmol Vis Sci. 1993;34(13):3574-3578.

[208] Barchiesi BJ, Eckel RH, Ellis PP. The cornea and disorders of lipid metabolism. Surv Ophthalmol. 1991;36(1):1-22.

[209] Winder AF, Borysiewicz LK. Corneal opacification and familial disorders affecting plasma high-density lipoprotein. Birth Defects Orig Artic Ser. 1982;18(6):433-440.

[210] Bron AJ. Corneal changes in the dislipoproteinaemias. Cornea. 1989;8(2):135-140.

[211] Schumacher MM, Jun DJ, Johnson BM, DeBose-Boyd RA. UbiA prenyltransferase domain-containing protein-1 modulates HMG-CoA reductase degradation to coordinate synthesis of sterol and nonsterol isoprenoids. J Biol Chem. 2018;293(1):312-323.

[212] Cao J, Wang J, Qi W, et al. Ufd1 is a cofactor of gp78 and plays a key role in cholesterol metabolism by regulating the stability of HMG-CoA reductase. Cell Metab. 2007;6(2):115-128.

[213] Jiang LY, Jiang W, Tian N, et al. Ring finger protein 145 (RNF145) is a ubiquitin ligase for sterol-induced degradation of HMG-CoA reductase. J Biol Chem. 2018;293(11):4047-4055.

[214] Sever N, Yang T, Brown MS, Goldstein JL, DeBose-Boyd RA. Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. Mol Cell. 2003;11(1):25-33.

[215] Song BL, Sever N, DeBose-Boyd RA. Gp78, a membrane-anchored ubiquitin ligase, associates with Insig-1 and couples sterol-regulated ubiquitination to degradation of HMG CoA reductase. Mol Cell. 2005;19(6):829-840.

[216] Tsai YC, Leichner GS, Pearce MM, et al. Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system. Mol Biol Cell. 2012;23(23):4484-4494.

[217] Menzies SA, Volkmar N, van den Boomen DJ, et al. The sterol-responsive RNF145 E3 ubiquitin ligase mediates the degradation of HMG-CoA reductase together with gp78 and Hrd1. Elife. 2018;7:e40009.

[218] Schumacher MM, Jun DJ, Jo Y, Seemann J, DeBose-Boyd RA. Geranylgeranyl-regulated transport of the prenyltransferase UBIAD1 between membranes of the ER and Golgi. J Lipid Res. 2016;57(7):1286-1299.

[219] Jun DJ, Schumacher MM, Hwang S, Kinch LN, Grishin NV, DeBose-Boyd RA. Schnyder corneal dystrophy-associated UBIAD1 is defective in MK-4 synthesis and resists autophagy-mediated degradation. J Lipid Res. 2020;61(5):746-757.

[220] Shin S, Zhou H, He C, et al. Qki activates Srebp2-mediated cholesterol biosynthesis for maintenance of eye lens transparency. Nat Commun. 2021;12(1):3005.

[221] Widomska J, Subczynski WK. Why is very high cholesterol content beneficial for the eye lens but negative for other organs? Nutrients. 2019;11(5):1083.

[222] De Vries AC, Vermeer MA, Bredman JJ, Bär PR, Cohen LH. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin. Exp Eye Res. 1993;56(4):393-399.

[223] Cenedella RJ, Kuszak JR, Al-Ghoul KJ, Qin S, Sexton PS. Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats. J Lipid Res. 2003;44(1):198-211.

[224] Enkavi G, Javanainen M, Kulig W, Róg T, Vattulainen I. Multiscale simulations of biological membranes: the challenge to understand biological phenomena in a living substance. Chem Rev. 2019;119(9):5607-5774.

[225] Mainali L, Raguz M, O'Brien WJ, Subczynski WK. Properties of membranes derived from the total lipids extracted from the human lens cortex and nucleus. Biochim Biophys Acta. 2013;1828(6):1432-1440.

[226] Plesnar E, Szczelina R, Subczynski WK, Pasenkiewicz-Gierula M. Is the cholesterol bilayer domain a barrier to oxygen transport into the eye lens? Biochim Biophys Acta Biomembr. 2018;1860(2):434-441.

[227] Goodwin H, Brooks BP, Porter FD. Acute postnatal cataract formation in Smith-Lemli-Opitz syndrome. Am J Med Genet A. 2008;146a(2):208-211.

[228] Hübner C, Hoffmann GF, Charpentier C, et al. Decreased plasma ubiquinone-10 concentration in patients with mevalonate kinase deficiency. Pediatr Res. 1993;34(2):129-133.

[229] Hua H, Yang T, Huang L, et al. Protective effects of lanosterol synthase up-regulation in UV-B-induced oxidative stress. Front Pharmacol. 2019;10:947.

[230] Zou X, Wang H, Zhou D, et al. The polymorphism rs2968 of LSS gene confers susceptibility to age-related cataract. DNA Cell Biol. 2020;39(11):1970-1975.

[231] Chen XJ, Hu LD, Yao K, Yan YB. Lanosterol and 25-hydroxycholesterol dissociate crystallin aggregates isolated from cataractous human lens via different mechanisms. Biochem Biophys Res Commun. 2018;506(4):868-873.

[232] Chang JR, Koo E, Agrón E, et al. Risk factors associated with incident cataracts and cataract surgery in the age-related eye disease study (AREDS): AREDS report number 32. Ophthalmology. 2011;118(11):2113-2119.

[233] McCarty CA, Nanjan MB, Taylor HR. Attributable risk estimates for cataract to prioritize medical and public health action. Invest Ophthalmol Vis Sci. 2000;41(12):3720-3725.

[234] Borchman D, Ramasubramanian A, Foulks GN. Human meibum cholesteryl and wax ester variability with age, sex, and meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2019;60(6):2286-2293.

[235] Goto E, Dogru M, Fukagawa K, et al. Successful tear lipid layer treatment for refractory dry eye in office workers by low-dose lipid application on the full-length eyelid margin. Am J Ophthalmol. 2006;142(2):264-270.

[236] Choi HR, Lee JH, Lee HK, Song JS, Kim HC. Association between dyslipidemia and dry eye syndrome among the korean middle-aged population. Cornea. 2020;39(2):161-167.

[237] Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. Jama. 2004;291(3):335-342.

[238] Opreanu M, Tikhonenko M, Bozack S, et al. The unconventional role of acid sphingomyelinase in regulation of retinal microangiopathy in diabetic human and animal models. Diabetes. 2011;60(9):2370-2378.

[239] Aldebasi YH, Mohieldein AH, Almansour YS, Almutairi BL. Dyslipidemia and lipid peroxidation of Saudi type 2 diabetics with proliferative retinopathy. Saudi Med J. 2013;34(6):616-622.

[240] Chung YR, Park SW, Choi SY, et al. Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. Cardiovasc Diabetol. 2017;16(1):4.

[241] Hammer SS, Vieira CP, McFarland D, et al. Fasting and fasting-mimicking treatment activate SIRT1/LXRα and alleviate diabetes-induced systemic and microvascular dysfunction. Diabetologia. 2021;64(7):1674-1689.

[242] Pettersson AM, Stenson BM, Lorente-Cebrián S, et al. LXR is a negative regulator of glucose uptake in human adipocytes. Diabetologia. 2013;56(9):2044-2054.

[243] Tian B, Al-Moujahed A, Bouzika P, et al. Atorvastatin promotes phagocytosis and attenuates pro-inflammatory response in human retinal pigment epithelial cells. Sci Rep. 2017;7(1):2329.

[244] Gnanaguru G, Wagschal A, Oh J, et al. Targeting of miR-33 ameliorates phenotypes linked to age-related macular degeneration. Mol Ther. 2021;29(7):2281-2293.

[245] Kim YK, Hong HK, Yoo HS, Park SP, Park KH. AICAR upregulates ABCA1/ABCG1 expression in the retinal pigment epithelium and reduces Bruch's membrane lipid deposit in ApoE deficient mice. Exp Eye Res. 2021;213:108854.

[246] Hussain G, Wang J, Rasul A, et al. Role of cholesterol and sphingolipids in brain development and neurological diseases. Lipids Health Dis. 2019;18(1):26.

[247] Preston Mason R, Tulenko TN, Jacob RF. Direct evidence for cholesterol crystalline domains in biological membranes: role in human pathobiology. Biochim Biophys Acta. 2003;1610(2):198-207.

RIGHTS & PERMISSIONS

2024 2024 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.